Last reviewed · How we verify

NCT04933097: SARCO-RA

Evaluation of a New Screening Method for Sarcopenia in Rheumatoid Arthritis

Completed NA Last updated 17 May 2024
What this trial tests

NA trial testing Microfet2® in Rheumatoid Arthritis in 164 participants. Completed in 16 May 2024.

Timeline
29 July 2021
Primary endpoint
16 May 2024
16 May 2024

Quick facts

Lead sponsorCHU de Reims
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment164
Start date29 July 2021
Primary completion16 May 2024
Estimated completion16 May 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of a new screening method for sarcopenia in rheumatoid arthritis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

Other CHU de Reims trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04933097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing